Department of Urology, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
International Medical Center, University of Tsukuba Affiliated Hospital, 2-1-1, Amakubo, Tsukuba, Ibaraki, 305-8576, Japan.
Int J Clin Oncol. 2024 Mar;29(3):318-324. doi: 10.1007/s10147-023-02457-0. Epub 2024 Jan 24.
BACKGROUND: To identify the prognostic impact of treatment centralization in patients with testicular germ cell tumors (TGCT). METHODS: We used a hospital-based cancer registry data in Japan to extract seminoma and non-seminoma cases that were diagnosed in 2013, histologically confirmed, and received the first course of treatment. To compare the 5-years overall survival (OS) rates of patients stratified by institutional care volume, we performed a Cox proportional hazards regression analysis using inverse probability of treatment weighting (IPTW) method to adjust patient backgrounds. RESULTS: A total of 1767 TGCT patients were identified. The 5-years OS rates for stage II and III TGCT patients treated at low-volume institutions (< 7 cases) were significantly worse than high-volume institutions (≥ 7 cases) (91.2% vs. 83.4%, p = 0.012). Histological stratification revealed that 5-year OS rates for stage II and III seminoma patients in the low-volume group were significantly worse than the high-volume group (93.5% vs. 84.5%, p = 0.041). Multivariate OS analysis using an IPTW-matched cohort showed that institutional care volume was an independent prognostic factor (hazard ratio 2.13 [95% confidence interval: 1.23-3.71], p = 0.0072). CONCLUSION: Our results indicate that stage II and III TGCT patients experience lower survival rates at low-volume institutions and would benefit from treatment centralization.
背景:本研究旨在明确治疗集中化对睾丸生殖细胞肿瘤(TGCT)患者的预后影响。
方法:我们利用日本基于医院的癌症登记数据,提取了 2013 年诊断、组织学确诊且接受首次治疗的精原细胞瘤和非精原细胞瘤病例。为了比较不同机构治疗量分层患者的 5 年总生存率(OS),我们采用逆概率治疗加权(IPTW)法进行 Cox 比例风险回归分析,以调整患者背景。
结果:共纳入 1767 例 TGCT 患者。低治疗量机构(<7 例)治疗的 II 期和 III 期 TGCT 患者的 5 年 OS 率明显低于高治疗量机构(≥7 例)(91.2% vs. 83.4%,p=0.012)。组织学分层显示,低治疗量组 II 期和 III 期精原细胞瘤患者的 5 年 OS 率明显低于高治疗量组(93.5% vs. 84.5%,p=0.041)。采用 IPTW 匹配队列进行多变量 OS 分析显示,机构治疗量是独立的预后因素(风险比 2.13 [95%置信区间:1.23-3.71],p=0.0072)。
结论:本研究结果表明,II 期和 III 期 TGCT 患者在低治疗量机构的生存率较低,从治疗集中化中获益。
World J Urol. 2022-12
Jpn J Clin Oncol. 2021-5-28
Clin Genitourin Cancer. 2018-2-23